After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...